IMPLANET Reports its 2024 First-Quarter Revenue
- +10% growth in the French market vs. 2023 Q1
- Continued expansion of the SMTP surgical equipment distribution activity
2024 First quarter
Revenue (in € thousands – IFRS1) |
2024 Q1 |
2023 Q1 |
Change % |
|
|
|
|
|
1,032 |
942 |
+10% |
|
314 |
459 |
-32% |
Rest of the world |
618 |
674 |
-8% |
Spine revenue |
1,964 |
2,075 |
-5% |
Medical equipment (SMTP) |
247 |
124 |
+100% |
Services (MADISONTM) |
12 |
9 |
+41% |
Total revenue 1st quarter |
2,223 |
2,208 |
+1% |
Spine activity generated revenue of €1.96 million in the first quarter of 2024, down 5% compared with revenue of €2.8 million in the first quarter of 2023.
Activity in
The Company is also continuing the rollout of its medical equipment distribution activity with Sanyou Medical subsidiary SMTP’s ultrasound surgical scalpel. The revenue generated by this activity in the first quarter of 2024 was €0.24 million, double the €0.12 million recorded in the same period of the previous year.
Cash position
As of
As a reminder, the Company announced on
The Company also concluded an agreement with some of its lenders (Banque Populaire Méditerranée,
In view of these elements, and the cash consumption forecasts based on current activity assumptions and anticipated business developments with Sanyou Medical over the 2024 and 2025 financial years, the Company considers that it will be able to cover the financing requirements of its operations for the next twelve months.
Key 2024 Q1 events
-
Completion of the capital increase announced on
January 4, 2024 , raising €5.5 million through the issue of 83,924,897 new shares; -
Appointment of
Max W. Painter as Vice President and General Manager ofIMPLANET's US subsidiary.
2024 strategy and outlook
-
Finalize the registration of existing products within the framework of the European Medical Device Regulation (MDR).
-
Reinvigorate the Company’s presence in
the United States :- strengthen the resources and commercial means made available to the historical team;
-
strengthen the Company’s direct approach by expanding the scientific team of opinion leaders;
-
Strengthen market momentum and the product offering:
- deploy the commercial and technological partnership with Sanyou Medical to jointly develop an innovative new European range of hybrid posterior fixation;
-
initiate the distribution of the JAZZ® platform in
China (the world’s largest spine market by volume) with Sanyou Medical.
Upcoming financial event
-
2024 First-Half Revenue,
July 9, 2024 , after market
About
Founded in 2007,
For further information, please visit www.Implanet.com.
1 Unaudited
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409733252/en/
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com
NewCap
Investor Relations
Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
Source: